CRSP CRISPR Therapeutics AG: institutional ownership and insider trading
549 funds reported holding $5.75B of CRISPR Therapeutics AG in their latest 13F filings; in Q2 2026 funds net sold $124M, with 72 new positions and 48 funds selling out; over the last 12 months insiders bought $0 and sold $17.9M on the open market.
Famous investors holding CRSP
- Cathie Wood (ARK Investment Management): $516M, 3.4% of the portfolio
- Two Sigma (Two Sigma Investments): $108M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $55.0M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $55.2M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $24.0M, 0.0% of the portfolio
Largest institutional holders of CRSP
- Banque Cantonale Vaudoise — $1.31B
- ARK Investment Management LLC — $516M
- BlackRock, Inc. (BLK) — $455M
- Orbis Allan Gray Ltd — $297M
- Capital World Investors — $259M
- STATE STREET CORP (STT, STT-PG) — $236M
- GSK plc (GSK, GLAXF) — $176M
- GEODE CAPITAL MANAGEMENT, LLC — $137M
- VANGUARD GROUP INC — $119M
- T. Rowe Price Investment Management, Inc. — $112M
Recent CRSP insider trades
- Oct 19, 2026: Kulkarni Samarth sold 47,837 shares ($2.38M)
- Oct 14, 2026: George Simeon sold 14,514 shares ($720K)
- Oct 14, 2026: Kulkarni Samarth sold 4,098 shares ($202K)
- Oct 14, 2026: Kasinger James R. sold 1,040 shares ($51.2K)
5%+ owners
- ARK Investment Management LLC: 11.8% (Schedule 13G/A, filed Apr 30, 2026)
- BlackRock, Inc.: 8.3% (Schedule 13G/A, filed Jul 27, 2026)
- ORBIS INVESTMENT MANAGEMENT LTD: 5.6% (Schedule 13G/A, filed Aug 14, 2026)
- Capital World Investors: 5.1% (Schedule 13G, filed May 14, 2026)